These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 31063758)

  • 1. YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells.
    White SM; Avantaggiati ML; Nemazanyy I; Di Poto C; Yang Y; Pende M; Gibney GT; Ressom HW; Field J; Atkins MB; Yi C
    Dev Cell; 2019 May; 49(3):425-443.e9. PubMed ID: 31063758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma.
    Benton D; Yee Chow H; Karchugina S; Chernoff J
    PLoS One; 2024; 19(7):e0305121. PubMed ID: 39083549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice.
    Park J; Kim JS; Nahm JH; Kim SK; Lee DH; Lim DS
    Mol Cells; 2020 May; 43(5):491-499. PubMed ID: 32451369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivators.
    Lavado A; He Y; Paré J; Neale G; Olson EN; Giovannini M; Cao X
    Development; 2013 Aug; 140(16):3323-34. PubMed ID: 23863479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stabilization of Motin family proteins in NF2-deficient cells prevents full activation of YAP/TAZ and rapid tumorigenesis.
    Wang Y; Zhu Y; Gu Y; Ma M; Wang Y; Qi S; Zeng Y; Zhu R; Wang X; Yu P; Xu J; Shu Y; Yu FX
    Cell Rep; 2021 Aug; 36(8):109596. PubMed ID: 34433060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.
    Moroishi T; Park HW; Qin B; Chen Q; Meng Z; Plouffe SW; Taniguchi K; Yu FX; Karin M; Pan D; Guan KL
    Genes Dev; 2015 Jun; 29(12):1271-84. PubMed ID: 26109050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
    Hyun J; Al Abo M; Dutta RK; Oh SH; Xiang K; Zhou X; Maeso-Díaz R; Caffrey R; Sanyal AJ; Freedman JA; Patierno SR; Moylan CA; Abdelmalek MF; Diehl AM
    J Hepatol; 2021 Sep; 75(3):623-633. PubMed ID: 33964370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Hippo pathway member Nf2 is required for inner cell mass specification.
    Cockburn K; Biechele S; Garner J; Rossant J
    Curr Biol; 2013 Jul; 23(13):1195-201. PubMed ID: 23791728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.
    Li W; Cooper J; Zhou L; Yang C; Erdjument-Bromage H; Zagzag D; Snuderl M; Ladanyi M; Hanemann CO; Zhou P; Karajannis MA; Giancotti FG
    Cancer Cell; 2014 Jul; 26(1):48-60. PubMed ID: 25026211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway.
    Wang C; Gu C; Jeong KJ; Zhang D; Guo W; Lu Y; Ju Z; Panupinthu N; Yang JY; Gagea MM; Ng PK; Zhang F; Mills GB
    Cancer Res; 2017 Apr; 77(7):1637-1648. PubMed ID: 28202507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals.
    Zhang N; Bai H; David KK; Dong J; Zheng Y; Cai J; Giovannini M; Liu P; Anders RA; Pan D
    Dev Cell; 2010 Jul; 19(1):27-38. PubMed ID: 20643348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.
    Striedinger K; VandenBerg SR; Baia GS; McDermott MW; Gutmann DH; Lal A
    Neoplasia; 2008 Nov; 10(11):1204-12. PubMed ID: 18953429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous knockdown of YAP and TAZ increases apoptosis of hepatocellular carcinoma cells under hypoxic condition.
    Yan B; Li T; Shen L; Zhou Z; Liu X; Wang X; Sun X
    Biochem Biophys Res Commun; 2019 Jul; 515(2):275-281. PubMed ID: 31146919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidation of WW domain ligand binding specificities in the Hippo pathway reveals STXBP4 as YAP inhibitor.
    Vargas RE; Duong VT; Han H; Ta AP; Chen Y; Zhao S; Yang B; Seo G; Chuc K; Oh S; El Ali A; Razorenova OV; Chen J; Luo R; Li X; Wang W
    EMBO J; 2020 Jan; 39(1):e102406. PubMed ID: 31782549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma.
    Li Y; Yang SR; Chen YB; Adusumilli PS; Bialik A; Bodd FM; Ladanyi M; Lopardo J; Offin MD; Rusch VW; Travis WD; Zauderer MG; Chang JC; Sauter JL
    Mod Pathol; 2023 Mar; 36(3):100030. PubMed ID: 36788094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
    Lamar JM; Xiao Y; Norton E; Jiang ZG; Gerhard GM; Kooner S; Warren JSA; Hynes RO
    J Biol Chem; 2019 Feb; 294(7):2302-2317. PubMed ID: 30559289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
    James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
    Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of store-operated calcium entry (SOCE) suppresses glioblastoma growth by inhibiting the Hippo pathway transcriptional coactivators YAP/TAZ.
    Liu Z; Wei Y; Zhang L; Yee PP; Johnson M; Zhang X; Gulley M; Atkinson JM; Trebak M; Wang HG; Li W
    Oncogene; 2019 Jan; 38(1):120-139. PubMed ID: 30082911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice.
    Moya IM; Castaldo SA; Van den Mooter L; Soheily S; Sansores-Garcia L; Jacobs J; Mannaerts I; Xie J; Verboven E; Hillen H; Algueró-Nadal A; Karaman R; Van Haele M; Kowalczyk W; De Waegeneer M; Verhulst S; Karras P; van Huffel L; Zender L; Marine JC; Roskams T; Johnson R; Aerts S; van Grunsven LA; Halder G
    Science; 2019 Nov; 366(6468):1029-1034. PubMed ID: 31754005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Merlin/NF2-Lin28B-let-7 Is a Tumor-Suppressive Pathway that Is Cell-Density Dependent and Hippo Independent.
    Hikasa H; Sekido Y; Suzuki A
    Cell Rep; 2016 Mar; 14(12):2950-61. PubMed ID: 26997273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.